GLAUKOS Corp (GKOS) stock
GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 7/30219% above fair value
$245.72−0.31 (-0.13%)
Close on Nov 13, 2026Market cap $14.55BP/E –Yield –
Glaukos r&d expenses
Research and development expenses are spending on new products and technology.
Glaukos's R&D Expenses for the twelve months ending Sep 30, 2026 was $201.43M, up 52.3% year over year. For fiscal 2025 it was $150.61M, up 10.4% from the year before. Over ten years it grew 19.6% a year on average. The highest annual figure on record is $150.61M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.61M | +10.4% |
| FY2024 | Dec 31, 2024 | $136.43M | -1.7% |
| FY2023 | Dec 31, 2023 | $138.77M | +12.6% |
| FY2022 | Dec 31, 2022 | $123.27M | +22.1% |
| FY2021 | Dec 31, 2021 | $101.00M | +18.3% |
| FY2020 | Dec 31, 2020 | $85.39M | +25.0% |
| FY2019 | Dec 31, 2019 | $68.31M | +37.5% |
| FY2018 | Dec 31, 2018 | $49.68M | +27.7% |
| FY2017 | Dec 31, 2017 | $38.91M | +33.1% |
| FY2016 | Dec 31, 2016 | $29.22M | +16.7% |
| FY2015 | Dec 31, 2015 | $25.05M | +30.4% |
| FY2014 | Dec 31, 2014 | $19.21M | +23.8% |
| FY2013 | Dec 31, 2013 | $15.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $30.95M | +15.2% |
| Q2 FY2026 | Jun 30, 2026 | $51.30M | +40.4% |
| Q1 FY2026 | Mar 31, 2026 | $44.15M | +36.4% |
| Q4 FY2025 | Dec 31, 2025 | $75.03M | +105.4% |
| Q3 FY2025 | Sep 30, 2025 | $26.86M | -22.7% |
| Q2 FY2025 | Jun 30, 2025 | $36.54M | +6.1% |
| Q1 FY2025 | Mar 31, 2025 | $32.35M | +5.3% |
| Q4 FY2024 | Dec 31, 2024 | $36.53M | -1.4% |
| Q3 FY2024 | Sep 30, 2024 | $34.75M | +4.3% |
| Q2 FY2024 | Jun 30, 2024 | $34.43M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $30.73M | -12.6% |
| Q4 FY2023 | Dec 31, 2023 | $37.06M | +3.5% |
| Q3 FY2023 | Sep 30, 2023 | $33.30M | +15.3% |
| Q2 FY2023 | Jun 30, 2023 | $33.23M | +4.8% |
| Q1 FY2023 | Mar 31, 2023 | $35.17M | +30.9% |
| Q4 FY2022 | Dec 31, 2022 | $35.81M | +34.2% |
| Q3 FY2022 | Sep 30, 2022 | $28.87M | +0.1% |
| Q2 FY2022 | Jun 30, 2022 | $31.71M | +30.7% |
| Q1 FY2022 | Mar 31, 2022 | $26.88M | +26.7% |
| Q4 FY2021 | Dec 31, 2021 | $26.68M | +25.6% |
| Q3 FY2021 | Sep 30, 2021 | $28.85M | +42.1% |
| Q2 FY2021 | Jun 30, 2021 | $24.26M | +27.9% |
| Q1 FY2021 | Mar 31, 2021 | $21.22M | -14.7% |
| Q4 FY2020 | Dec 31, 2020 | $21.24M | +6.1% |
| Q3 FY2020 | Sep 30, 2020 | $20.30M | +17.5% |
| Q2 FY2020 | Jun 30, 2020 | $18.97M | +11.1% |
| Q1 FY2020 | Mar 31, 2020 | $24.87M | +78.6% |
| Q4 FY2019 | Dec 31, 2019 | $20.03M | +54.6% |
| Q3 FY2019 | Sep 30, 2019 | $17.28M | +30.9% |
| Q2 FY2019 | Jun 30, 2019 | $17.07M | +35.4% |
| Q1 FY2019 | Mar 31, 2019 | $13.93M | +27.7% |
| Q4 FY2018 | Dec 31, 2018 | $12.96M | +23.1% |
| Q3 FY2018 | Sep 30, 2018 | $13.20M | +34.6% |
| Q2 FY2018 | Jun 30, 2018 | $12.61M | +30.9% |
| Q1 FY2018 | Mar 31, 2018 | $10.91M | +22.0% |
| Q4 FY2017 | Dec 31, 2017 | $10.53M | +42.2% |
| Q3 FY2017 | Sep 30, 2017 | $9.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.40M | – |
See a number that looks wrong?